Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Comorbidity burden in patients with chronic GVHD.

Wood WA, Chai X, Weisdorf D, Martin PJ, Cutler C, Inamoto Y, Wolff D, Pavletic SZ, Pidala J, Palmer JM, Arora M, Arai S, Jagasia M, Storer B, Lee SJ, Mitchell S.

Bone Marrow Transplant. 2013 Nov;48(11):1429-36. doi: 10.1038/bmt.2013.70. Epub 2013 May 13.

2.

Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease.

Vaughn JE, Gooley T, Maziarz RT, Pulsipher MA, Bhatia S, Maloney DG, Sandmaier BM, Flowers ME, Storb R, Sorror ML.

Br J Haematol. 2015 Nov;171(3):411-6. doi: 10.1111/bjh.13591. Epub 2015 Jul 20.

3.

Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.

Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M.

Biol Blood Marrow Transplant. 2012 Nov;18(11):1727-33. doi: 10.1016/j.bbmt.2012.06.014. Epub 2012 Jul 2.

4.

Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.

Sorror ML, Martin PJ, Storb RF, Bhatia S, Maziarz RT, Pulsipher MA, Maris MB, Davis C, Deeg HJ, Lee SJ, Maloney DG, Sandmaier BM, Appelbaum FR, Gooley TA.

Blood. 2014 Jul 10;124(2):287-95. doi: 10.1182/blood-2014-01-550566. Epub 2014 May 5.

5.

Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.

Barba P, Piñana JL, Martino R, Valcárcel D, Amorós A, Sureda A, Briones J, Delgado J, Brunet S, Sierra J.

Biol Blood Marrow Transplant. 2010 Mar;16(3):413-20. doi: 10.1016/j.bbmt.2009.11.008. Epub 2009 Nov 14.

6.

Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study.

Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL, Ho VT, Horowitz MM, Pasquini MC.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1479-87. doi: 10.1016/j.bbmt.2015.04.004. Epub 2015 Apr 7.

7.

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities.

Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C, Maloney DG, Storb R.

Blood. 2004 Aug 15;104(4):961-8. Epub 2004 Apr 27.

8.

National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.

Saillard C, Crocchiolo R, Furst S, El-Cheikh J, Castagna L, Signori A, Oudin C, Faucher C, Lemarie C, Chabannon C, Granata A, Blaise D.

Leuk Lymphoma. 2014 May;55(5):1106-12. doi: 10.3109/10428194.2013.820285. Epub 2014 Feb 4.

PMID:
23822538
9.

A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia.

Terwey TH, Hemmati PG, Martus P, Dietz E, Vuong LG, Massenkeil G, Dörken B, Arnold R.

Haematologica. 2010 May;95(5):810-8. doi: 10.3324/haematol.2009.011809. Epub 2009 Dec 8.

10.

Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.

Naik S, Martinez C, Leung K, Sasa G, Nguyen NY, Wu MF, Gottschalk S, Brenner M, Heslop H, Krance R.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1266-72. doi: 10.1016/j.bbmt.2015.02.024. Epub 2015 Mar 10.

11.

The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.

Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M, Fanin R, Boccadoro M, Corradini P.

Leukemia. 2009 Jun;23(6):1131-8. doi: 10.1038/leu.2009.1. Epub 2009 Feb 5.

PMID:
19194465
12.

Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.

Inagaki J, Moritake H, Nishikawa T, Hyakuna N, Okada M, Suenobu S, Nagai K, Honda Y, Shimomura M, Fukano R, Noguchi M, Kurauchi K, Tanioka S, Okamura J.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1973-80. doi: 10.1016/j.bbmt.2015.07.025. Epub 2015 Jul 31.

13.

Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.

Sabry W, Le Blanc R, Labbé AC, Sauvageau G, Couban S, Kiss T, Busque L, Cohen S, Lachance S, Roy DC, Roy J.

Biol Blood Marrow Transplant. 2009 Aug;15(8):919-29. doi: 10.1016/j.bbmt.2009.04.004. Epub 2009 Jun 10.

14.

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F, Agura ED, Hari P, Bruno B, McSweeney PA, Maris MB, Maziarz RT, Langston AA, Bethge W, Vindeløv L, Franke GN, Laport GG, Yeager AM, Hübel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM.

J Clin Oncol. 2013 Apr 20;31(12):1530-8. doi: 10.1200/JCO.2012.45.0247. Epub 2013 Mar 11.

16.

Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.

Duncan CN, Majhail NS, Brazauskas R, Wang Z, Cahn JY, Frangoul HA, Hayashi RJ, Hsu JW, Kamble RT, Kasow KA, Khera N, Lazarus HM, Loren AW, Marks DI, Maziarz RT, Mehta P, Myers KC, Norkin M, Pidala JA, Porter DL, Reddy V, Saber W, Savani BN, Schouten HC, Steinberg A, Wall DA, Warwick AB, Wood WA, Yu LC, Jacobsohn DA, Sorror ML.

Biol Blood Marrow Transplant. 2015 Jan;21(1):151-8. doi: 10.1016/j.bbmt.2014.10.006. Epub 2014 Oct 12.

17.

GVHD-associated chronic kidney disease after allogeneic haematopoietic cell transplantation.

Sakellari I, Barbouti A, Bamichas G, Mallouri D, Kaloyannidis P, Fragidis S, Batsis I, Apostolou C, Karpouza A, Yannaki E, Smias C, Sombolos K, Anagnostopoulos A.

Bone Marrow Transplant. 2013 Oct;48(10):1329-34. doi: 10.1038/bmt.2013.55. Epub 2013 Apr 15.

PMID:
23584436
18.

Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.

Devillier R, Fürst S, El-Cheikh J, Castagna L, Harbi S, Granata A, Crocchiolo R, Oudin C, Mohty B, Bouabdallah R, Chabannon C, Stoppa AM, Charbonnier A, Broussais-Guillaumot F, Calmels B, Lemarie C, Rey J, Vey N, Blaise D.

Biol Blood Marrow Transplant. 2014 Mar;20(3):370-4. doi: 10.1016/j.bbmt.2013.11.030. Epub 2013 Dec 4.

19.

Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation.

Herzberg PY, Heussner P, Mumm FH, Horak M, Hilgendorf I, von Harsdorf S, Hemmati P, Rieger K, Greinix H, Freund M, Lee SJ, Holler E, Wolff D.

Biol Blood Marrow Transplant. 2010 Dec;16(12):1707-17. doi: 10.1016/j.bbmt.2010.05.018. Epub 2010 Jun 9.

20.

Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes.

Cho BS, Lee SE, Song HH, Lee JH, Yahng SA, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW.

Biol Blood Marrow Transplant. 2012 Jul;18(7):1136-43. doi: 10.1016/j.bbmt.2012.01.010. Epub 2012 Jan 16.

Supplemental Content

Support Center